President Trump's Drug Pricing Policies Could Hurt Drugmakers' Profits. Time to Sell Pharma Stocks?

The article argues that Trump’s MFN drug-pricing policy could pressure U.S. pharma profits, but highlights Johnson & Johnson and Roche as relatively resilient due to diversification. Johnson & Johnson is expected to generate $100.8 billion in revenue this year, up 7% year over year, while Roche is advancing a deep pipeline and plans to launch up to 19 new medicines by decade-end. Roche also agreed to buy SAGA Diagnostics for up to $595 million, reinforcing its diagnostics platform as a hedge against pharmaceutical pricing pressure.

Analysis

The market is still pricing this as a blunt “bad for pharma” headline, but the second-order effect is a margin reallocation inside healthcare rather than a clean sector-wide compression. Price pressure on patent-heavy drug revenue should disproportionately hit companies with limited non-drug diversification and a higher mix of U.S. reimbursement exposure, while integrated platforms with devices, diagnostics, and ex-U.S. revenue can offset it through mix shift and operating leverage. In that framework, the better relative trade is not “own healthcare” but “own healthcare complexity.”

Johnson & Johnson’s real defense is not just diversification; it is that drug pricing pressure likely accelerates capital deployment into faster-growing, less politically sensitive adjacencies such as procedures and devices. If the RAS opportunity gains traction, the market may begin to value JNJ less as a mature pharma proxy and more as a quasi-medtech compounder, which supports multiple stability even if prescription pricing headlines worsen. The dividend remains important, but the bigger takeaway is that policy pressure could paradoxically improve the quality of JNJ’s earnings mix over 12-24 months.

Roche is even better insulated because diagnostics can act as a countercyclical growth engine if pharma repricing slows drug momentum. The SAGA-type MRD exposure is strategically relevant: payer adoption of earlier recurrence detection can expand test volumes even in a tighter reimbursement environment, and that creates a second revenue leg with lower policy beta than therapeutics. The consensus is missing that pricing reform may actually increase the value of pipeline diversification and diagnostics capabilities, not just reduce pharma multiples.

The main risk is timing: policy headlines can hit sentiment immediately, while the fundamental offsets play out over several quarters. If MFN implementation is diluted, delayed, or narrowed to a subset of drugs, the near-term selloff in high-quality diversified names will likely reverse faster than the broader biotech/pharma basket. The deeper tail risk is that investors extrapolate policy pressure into a permanent de-rating of all healthcare, when the winners will likely be the platform companies with the most optionality.

Key Decisions for Investors

• Long JNJ vs short IBB on a 3-6 month horizon: JNJ should show lower policy beta and better earnings stability than the biotech index if pricing headlines intensify; target 1.5-2.0x downside capture on the short leg.
• Add to JNJ on weakness below event-driven selloff levels; use a 6-12 month horizon and treat it as a quality defensives trade with dividend support plus multiple defense from device mix.
• Initiate long Roche as a 12-month relative-value hedge against U.S. pharma pricing reform; the setup is strongest if diagnostics adoption and pipeline updates remain intact while U.S.-centric peers rerate lower.
• Pair long JNJ / short a more concentrated U.S. pharma name with heavy Medicare exposure; the thesis is that diversified earnings streams will command a premium if MFN rhetoric escalates.
• Avoid chasing broad pharma basket shorts until policy details are concrete; the better risk/reward is selective shorting of names with limited non-drug offsets rather than indiscriminate sector beta.